Tralesinidase alfa

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameTralesinidase alfa
Drug Alias NameAlpha-N-acetyglucosaminidase-insulin-like-growth-factor-2 fusion proteinNAGLU-IGF2 fusion proteinTA-ERTBMN-250AX-250
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAlpha-N-acetylglucosaminidase replacements
TargetsAlpha-N-acetylglucosaminidase
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanTurkey +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesAllievex CorpSpruce Biosciences Inc
Inactive CompaniesN/A
Active IndicationsMucopolysaccharidosis III
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A